Influence of the mannoproteins of different strains of Starmerella bacillaris used in single and sequential fermentations on foamability, tartaric and protein stabilities of wines

Aim: In this work, seven strains of Starmerella bacillaris were analysed for their ability to release polysaccharides during alcoholic fermentation (AF), both in single-strain and in sequential AF together with Saccharomyces cerevisiae. Methods and results: A synthetic polysaccharide-free must was used to characterise the mannoproteins (MPs) released. The MPs were quantified, characterised in terms of carbohydrate composition, and tested to assess their ability to reduce protein and tartrate instabilities and their ability to affect the foaming properties of wine. Conclusions: All the tested strains in sequential AF increased the total MPs production. Moreover, the strains affected the MPs properties in different ways regarding tartaric and protein stabilities. The MPs released in sequential AF by some S. bacillaris strains showed a significant effect on protein stabilisation and tartaric stability. An effect on the foamability was found for MPs obtained in single-strain AFs of S. bacillaris

Caracterização do Queijo Artesanal de Alagoa - MG: parâmetros físicos, físicoquímicos, microbiológicos e sensoriais.

Resumo ? O conhecimento do processo de produção do leite e fabricação do queijo é fundamental para padronização e qualidade do queijo artesanal. Com este objetivo, utilizando entrevistas estruturadas, foram identificadas as variáveis que compõem o sistema de produção de leite e as etapas do processo de fabricação do queijo artesanal de Alagoa-MG. Os parâmetros físicos (diâmetro e altura), físico-químicos (umidade, matéria gorda no extrato seco, proteína e cloretos) e sensoriais foram pesquisados nos queijos de seis produtores com 14 dias de maturação. A pesquisa de L. monocytogenes e Salmonella spp. e a contagem de Staphylococcus coagulase positiva (SCP) e coliformes foi realizada no leite cru, assim como no queijo recém-fabricado e após sete, 14, 21 e 28 dias de maturação dos mesmos seis produtores do município de Alagoa. A produção de leite no município de Alagoa se caracteriza por um sistema semiextensivo com suplementação no cocho durante todo o ano. A área de 90% das propriedades é inferior a 30 ha, sendo 2/3 destas áreas constituídas de pastagens [Urochloa (Brachiaria) decumbens cv. Basilisk] manejadas sem adubação. Os rebanhos são constituídos, na sua maioria, por vacas Girolando ou mestiças (58%), sendo que 42% das vacas em lactação produzem entre 11 e 15 litros leite/dia. Em 2015 90% das queijeiras produziram até 14.000 kg de queijo. As análises microbiológicas revelaram a presença de SCP e de coliformes totais e termotolerantes no leite cru e nos queijos, em contagens acima do limite máximo estabelecido pela legislação em algumas propriedades. O número total desses microrganismos apresentou uma tendência de queda com o decorrer da maturação do queijo. As análises da composição dos queijos indicam que o queijo artesanal de Alagoa pode ser classificado como de baixa umidade e gordo. Em relação às características sensoriais, os queijos apresentaram consistência tendendo a dura, textura tendendo a fechada sem olhaduras, cor interna amarelada, sabor moderadamente salgado e tendendo a picante, odor moderadamente pronunciado. Para a produção de queijos com qualidade e segurança microbiológica é necessária a implementação de boas práticas na produção de leite, incluindo programas de controle de mastite, brucelose e tuberculose, e de boas práticas na fabricação de queijos.bitstream/item/209185/1/BOP-41-Queijo-Artesanal.pd

Levantamento de reconhecimento de baixa intensidade dos solos do Município de Campo Grande, MS.

O Levantamento de Reconhecimento de Baixa Intensidade dos Solos do Município de Campo Grande, que compreende cerca de 8.000 km2 da região Central do Estado de Mato Grosso do Sul, teve como objetivo imediato dar suporte ao Zoneamento Agroecológico deste estado. A identificação e a caracterização dos solos foram realizadas por meio de prospecção ao longo das estradas que cortam o município, sendo o mapeamento executado com o apoio de fotografias aéreas verticais na escala de 1:60.000, imagens orbitais do satélite Landsat 7, além de folhas planialtimétricas da Carta do Brasil na escala 1:100.000. O nível de detalhamento do mapa pedológico gerado é compatível com a escala 1:100.000. Foram identificadas no nível de subordem as seguintes classes de solos: Cambissolo Háplico; Gleissolo Háplico; Gleissolo Melânico; Latossolo Amarelo; Latossolo Vermelho; Neossolo Litólico; Neossolo Quarzarênico; Organossolo Háplico; Planossolo Háplico.bitstream/item/147403/1/BPD-235-Levantamento-Solos-Campo-Grande.pdf; bitstream/item/215692/1/Mapa-Levantamento-de-reconhecimento-de-baixa-intensidade-dos-solos-do-Municipio-de-Campo-Grande-MS-layout-atualizado-2020.pdfAcompanha 1 mapa, color. Escala 1:100.000. Mapa: Levantamento de reconhecimento de baixa intensidade dos solos do Município de Campo Grande - MS, layout atualizado em ago./2020, anexado ao registro

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

MUSiC: a model-unspecific search for new physics in proton–proton collisions at √s=13TeV

Results of the Model Unspecific Search in CMS (MUSiC), using proton–proton collision data recorded at the LHC at a centre-of-mass energy of 13TeV, corresponding to an integrated luminosity of 35.9fb-1, are presented. The MUSiC analysis searches for anomalies that could be signatures of physics beyond the standard model. The analysis is based on the comparison of observed data with the standard model prediction, as determined from simulation, in several hundred final states and multiple kinematic distributions. Events containing at least one electron or muon are classified based on their final state topology, and an automated search algorithm surveys the observed data for deviations from the prediction. The sensitivity of the search is validated using multiple methods. No significant deviations from the predictions have been observed. For a wide range of final state topologies, agreement is found between the data and the standard model simulation. This analysis complements dedicated search analyses by significantly expanding the range of final states covered using a model independent approach with the largest data set to date to probe phase space regions beyond the reach of previous general searches

Search for low-mass dilepton resonances in Higgs boson decays to four-lepton final states in proton–proton collisions at √s=13TeV

A search for low-mass dilepton resonances in Higgs boson decays is conducted in the four-lepton final state. The decay is assumed to proceed via a pair of beyond the standard model particles, or one such particle and a Z boson. The search uses proton–proton collision data collected with the CMS detector at the CERN LHC, corresponding to an integrated luminosity of 137 fb−1, at a center-of-mass energy √s = 13 TeV. No significant deviation from the standard model expectation is observed. Upper limits at 95% confidence level are set on model-independent Higgs boson decay branching fractions. Additionally, limits on dark photon and axion-like particle production, based on two specific models, are reported